Indian pharmaceutical exports to China fell to $287.42 million in the 2026 fiscal year due to regulatory hurdles and tough local competition. This decline contrasts with the broader 2% growth in India’s total pharma exports. The data highlights the ongoing struggle for Indian firms to gain a foothold in China, even while remaining heavily dependent on Chinese raw materials.
What Happened
In the fiscal year 2026, Indian pharmaceutical exports to China saw a decline of 11.54%, with total shipments falling to $287.42 million. This contraction is notable because it occurred while India’s total pharmaceutical exports grew by about 2% globally. The drop shows that while Indian drugmakers are finding success in other international markets, the world’s second-largest pharmaceutical market remains difficult to penetrate.
The Barriers To Entry
Indian drugmakers have faced several challenges in the Chinese market. These include non-tariff barriers, which are complex rules and standards that make it difficult for foreign goods to enter. Additionally, Chinese regulators have processes that can be time-consuming for foreign companies. Once a product is cleared, companies face intense price competition from domestic Chinese manufacturers. The local healthcare system often shows a strong preference for domestic products, making it hard for Indian companies to win significant market share in public hospitals.
Impact On Leading Players
Major Indian companies, such as Sun Pharma, Dr. Reddy's Laboratories, and Cipla, have dedicated significant resources to enter China. While firms like Dr. Reddy’s and Cipla have managed to bid for contracts to supply medicines to public hospitals, they are often undercut by local rivals who offer lower prices. This aggressive pricing strategy from local competitors has limited the ability of Indian companies to grow their revenue in the region, forcing them to rethink their business approach in China.
The Import Paradox
Even as Indian pharma exports to China struggle, India remains heavily dependent on China for the raw materials needed to make medicines. In FY26, India imported $3.7 billion worth of pharmaceutical materials from China, accounting for roughly 38.09% of India’s total pharmaceutical imports. These imports primarily consist of bulk drugs and intermediate ingredients. This creates a challenging scenario for the industry: the country relies heavily on Chinese supply chains to manufacture its own medicines, but finds it difficult to sell finished formulations back into the Chinese market.
What Investors Can Track
Investors monitoring these companies may look at how they manage their exposure to the Chinese market. The key monitorable will be whether Indian firms can improve their cost structures to compete with local Chinese prices, or if they will shift their expansion focus to other regions. Additionally, any updates on trade policy, regulatory easing, or changes in raw material costs from China will be important factors that could influence profit margins for Indian pharmaceutical manufacturers.